MORE►
biotech
Pegasus artwork in the lobby of Dallas' Pegasus Park, the home of the ARPA-H Customer Experience Hub. [Photo: Dallas Innovates]
The Last Word: Dallas Tops Site Selection’s Metro Rankings, ‘Double Shot’ of Life Sciences Investment Adds to Momentum
by Quincy Preston | Mar 5, 2024
According to a new report from Dallas-based JLL, society is accelerating the volume of data it creates at a rapid rate—and that data is foundational to how we work, live, and play. That's led to sharply increasing demand for data centers in a time of tightening supply, forcing a shift toward secondary and new, emerging markets.
by Quincy Preston |
Oct 16, 2023
The NFL and NBA icons—Clark Hunt and Dirk Nowitzki—will kick off and wrap up discussions on innovation and investment. They add to an "impressive speaker lineup" including Nextdoor Co-Founder Nirav Tolia and other trailblazing speakers. Here's the full roster.
MORE►
by Lance Murray |
Oct 6, 2023
It's national pasta month. The Texas mother, author, and philanthropist—married to Matthew McConaughey—has partnered with the Dallas-connected "better-for-you" pasta brand launched by Arcadia Biosciences. To entice families, it offers a "clean-plate guarantee."
MORE►
by Quincy Preston |
Sep 27, 2023
The rebrand "marks the start of our next chapter of growth," says Venture Dallas Chair Aaron Pierce. The nonprofit's 2023 summit, backed by JPMorgan Chase and Perot Jain, is set for October 25.
MORE►
Photo: gorodenkoff/iStock
Irving-Based Fluor Awarded More Than $1 Billion in Life Sciences Contracts
by Dallas Innovates | Staff Report | Jul 28, 2023
“Delivering these projects will help to increase the speed-to-market and meet the overwhelming demand for new medicines," said Richard Meserole, president of Fluor’s advanced technologies and life sciences business.
MORE►
by Quincy Preston |
Jul 26, 2023
From an old car parts garage, Vertex Founder Joshua Boger launched the Boston-based biotech giant in 1989, running it for two decades as CEO. Boger "unretired" in June to join fast-moving Alkeus Pharmaceuticals as executive chairman.
In Dallas, he shared the "mistakes" that led to his success with innovators at Pegasus Park. Here's his no-holds-barred dose of truth for all entrepreneurs.
In Dallas, he shared the "mistakes" that led to his success with innovators at Pegasus Park. Here's his no-holds-barred dose of truth for all entrepreneurs.
MORE►
by Quincy Preston |
Jul 18, 2023
Parker Health's cloud Health Management System is the first in the U.S. to build on the Fast Healthcare Interoperability Resources—or FHIR—standard to create an interoperable, affordable, and compliant cloud-based platform. The Parker Suite aims to unify patient-centric data, biometrics, diagnostic tools, patient outcomes, care delivery, practitioner engagement, and pharmaceuticals for the healthcare ecosystem.
MORE►
by Nicole Ward, DRC Data Journalist |
Jun 8, 2023
Elina Lavit, originally from the Soviet Union, charted a new course in 2021. Swapping San Francisco for Dallas, she's now steering business development at OncoNano Medicine, a North Texas biotech that aims to revolutionize cancer treatment.
MORE►
ConcertAI CEO Jeff Elton (left) and David Spetzler, president of Caris Life Sciences [Photo: ConcertAI]
Caris Life Sciences and ConcertAI Announce New Clinico-Genomic Research Platform
by Lance Murray | Jun 1, 2023
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
MORE►
by Quincy Preston |
May 18, 2023
The multi-billion investment firm’s two-property industrial deal in Philadelphia builds on its commitment to grow in the “critical sector.” Closer to home, NexPoint recently unveiled plans for a massive life sciences district in Plano. The proposed 200-acre TxS development would be a "major economic catalyst" for North Texas, the firm’s founder said in February.
MORE►
by Lance Murray |
May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
MORE►
by Dallas Innovates | Staff Report |
Mar 1, 2023
Dallas-Fort Worth is well known for its tech expertise. Now it being recognized as the place where technology meets life science—a convergence that’s driving rapid growth in the biotech ecosystem....
MORE►
Leading tech companies with a stake in North Texas are helping to shape the future with emerging technologies predicted to transform the world in 2023 and beyond. Clockwise from left: Flytrex and Brinker, Toyota and Google Cloud, Waymo, Texas Instruments, Bell, and Siemens Digital Industries Software. [Courtesy photos]
Emerging Trends: Three Futurists Predict The Tech That Comes Next
by Sandra Engelland | Feb 15, 2023
From AI to human longevity to xTech, North Texas experts George Brody of InfoNet of Things and Anurag Jain of Perot Jain, along with Mike Bechtel of Deloitte, predict a range of emerging technologies set to transform the world in 2023 and beyond.
MORE►
by Lance Murray |
Jan 11, 2023
Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has appointed Massoud Motamed, Ph.D., as vice president of quality.
Motamed brings nearly a decade of CGMP quality and compliance experience, including extensive experience in manufacturing and regulatory review of gene therapy products....
MORE►
by Lance Murray |
Dec 8, 2022
Southlake-based Renibus Therapeutics—a clinical-stage biotech company developing innovative products for cardiorenal diseases—has received $33 million in bridge financing to help it advance three drugs in its pipeline. The drugs are currently in various phases of trials.
MORE►
by Quincy Preston |
Nov 20, 2022
Fort Worth-based NanOlogy has completed the enrollment of 18 patients in a Phase 2a trial for its proprietary particle drug delivery with standard-of care therapy in nonoperable lung cancer patients....
MORE►
